YCT-529 is an experimental, non-hormonal male contraceptive developed by YourChoice Therapeutics. It acts as a selective inhibitor of the retinoic acid receptor alpha (RAR- Mechanism of Action: It functions by targeting the RAR-
If you are asking about a specific type of male contraceptive, or if you need to know how to open a RAR archive file (the format, rather than the "Male.rar" text), please clarify! Are you researching the ?
Based on your search request, here is the relevant review information for in the context of recent developments for a potential new product, focusing on the YCT-529 molecule, as of April 2026:
It is designed to be a "male pill" that targets only the necessary receptor, aimed at reducing side effects found in older, less specific studies (like those using BMS-189453).
Studies showed 100% sterility in mice after dosing, which was found to be fully reversible after drug discontinuation.
In July 2025, Communications Medicine published results showing the candidate was well-tolerated by male volunteers in a first-in-human study. As of January 2026, it is in active clinical development.
Active 1 Day
Active 1 Day
Active 1 Day
Active 1 Day
Active 5 Day
Active 1 Day
Active 1 Day
Active 1 Day
Active 1 Day
Active 1 Day
Colabors atively fabcate best breed and apcations through visionary value






Colabors atively fabcate best breed and apcations through visionary value






Colabors atively fabcate best breed and apcations through visionary value






Colabors atively fabcate best breed and apcations through visionary value






YCT-529 is an experimental, non-hormonal male contraceptive developed by YourChoice Therapeutics. It acts as a selective inhibitor of the retinoic acid receptor alpha (RAR- Mechanism of Action: It functions by targeting the RAR-
If you are asking about a specific type of male contraceptive, or if you need to know how to open a RAR archive file (the format, rather than the "Male.rar" text), please clarify! Are you researching the ?
Based on your search request, here is the relevant review information for in the context of recent developments for a potential new product, focusing on the YCT-529 molecule, as of April 2026:
It is designed to be a "male pill" that targets only the necessary receptor, aimed at reducing side effects found in older, less specific studies (like those using BMS-189453).
Studies showed 100% sterility in mice after dosing, which was found to be fully reversible after drug discontinuation.
In July 2025, Communications Medicine published results showing the candidate was well-tolerated by male volunteers in a first-in-human study. As of January 2026, it is in active clinical development.
You find us, finally, and you are already in love. More than 5.000.000 around the world already shared the same experience andng ares uses our system Joining us today just got easier!